Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences
- blonca9
- Nov 1, 2023
- 1 min read
Sarah Boyce explains the rationale for using AOCs against muscle disorders like myotonic dystrophy type 1 and DMD, and describes the clinical data Avidity has collected so far.